Edwards Lifesciences stock leans on its core heart valve business
Edwards Lifesciences (US28176E1082) remains focused on its structural heart therapies, particularly its core heart valve franchise. The company's business model relies on transcatheter aortic valve replacement systems and related products, with the SAPIEN family being a key product line. Investors are encouraged to focus on the company's execution and product cycle rather than broad market chatter, given its US-listed, large-cap healthcare status.
EW - Edwards Lifesciences Corp Volatility & Greeks
This article provides a detailed financial overview of Edwards Lifesciences Corp (EW), including its stock performance, market capitalization, income, sales, and various financial ratios. It also presents insider ownership and institutional ownership data, along with volatility measures and analyst recommendations. The data indicates strong recent performance and growth projections for the company.
KIDS,ATEC Volatility & Greeks
The article provides detailed financial and performance data for two medical device companies: OrthoPediatrics Corp (KIDS) and Alphatec Holdings Inc (ATEC). It includes current stock prices, market capitalization, earnings per share, sales figures, institutional and insider ownership, and various other financial ratios and performance metrics for both companies as of July 2nd.
CLPT - ClearPoint Neuro Inc Volatility & Greeks
This article provides a detailed financial overview of ClearPoint Neuro Inc (CLPT), including its stock performance, key financial metrics, and volatility indicators. It lists various financial ratios, employee and ownership data, and price performance over different periods. The data presented covers the company's valuation, profitability, growth rates, and short interest.
If You Invested $1,000 in Edwards Lifesciences Corp (EW)
This article analyzes the historical performance of investing $1,000 in Edwards Lifesciences Corp (EW) over various periods, showing returns ranging from +23.1% in one year to +184.2% over ten years. It also provides a detailed overview of Edwards Lifesciences, a medical technology company focused on structural heart disease, outlining its products, clinical evidence, corporate structure, and market position. The company's performance is compared to the S&P 500, indicating it has underperformed the benchmark over the past decade.
BWAY - Brainsway Ltd ADR Options
This article provides a detailed financial overview of Brainsway Ltd ADR (BWAY), including its recent stock performance, key financial metrics, and valuation ratios. It lists various indicators such as market capitalization, income, sales, P/E ratio, EPS growth, insider and institutional ownership, and profitability margins. The data suggests an in-depth look into the company's financial health and market position.
PEN - Penumbra Inc Volatility & Greeks
This article provides a detailed financial overview of Penumbra Inc (PEN), including its latest stock performance, key financial metrics, volatility data, and analyst recommendations. It covers various fundamental and technical indicators, insider and institutional ownership, and historical performance over different periods.
TMDX - Transmedics Group Inc Latest SEC Filings
This article provides the latest SEC filings information for Transmedics Group Inc (TMDX), along with comprehensive financial data. It includes key figures such as market capitalization, income, sales, various financial ratios, stock performance metrics, and analyst recommendations.
SIBN - SI-BONE Inc Latest SEC Filings
This article provides detailed financial data and performance metrics for SI-BONE Inc (SIBN), including its latest stock price, market capitalization, earnings per share, sales, and various financial ratios. It also lists insider and institutional ownership, analyst recommendations, and recent price performance over different periods. The information is presented as a snapshot of the company's financial health and stock market activity.
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of Edwards stock to contact them to discuss potential rights and options, including seeking corporate governance reforms or the return of funds to the company. Halper Sadeh LLC emphasizes that shareholder involvement can enhance transparency and management within the company.
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains
Edwards Lifesciences Corp. (EW) stock advanced by 2.59% on Thursday, closing at $94.37. Despite these daily gains, the stock underperformed when compared to its competitors, even as the S&P 500 Index remained mostly unchanged and the Dow Jones Industrial Average rose. This marked the stock's second consecutive day of increases.
TD Cowen Names Edwards Lifesciences as Top Medical Device Pick By Investing.com
TD Cowen has named Edwards Lifesciences (NYSE:EW) as its top medical device pick, reiterating a Buy rating after new seven-year clinical trial data reinforced the efficacy of its transcatheter aortic valve replacement (TAVR) intervention. The data from the PARTNER 3 trial showed TAVR and surgery have similar long-term outcomes for structural valve deterioration, with low overall event rates and comparable reintervention rates. This strong clinical evidence, coupled with a U.S. government proposal to expand TAVR coverage, underpins TD Cowen's confidence in Edwards Lifesciences' continued market share gains and future performance.
TD Cowen Names Edwards Lifesciences as Top Medical Device Pick By Investing.com
TD Cowen analyst Joshua Jennings has named Edwards Lifesciences Corp. (NYSE:EW) as his firm's top pick in the medical device sector, reiterating a Buy rating. This recommendation follows the presentation of seven-year follow-up data from the PARTNER 3 trial, which provided strong clinical evidence supporting Edwards' dominant market position in transcatheter aortic valve replacement (TAVR). The data indicated similar structural valve deterioration and bioprosthetic valve failure rates between TAVR and surgery in lower-risk patients.
INSP - Inspire Medical Systems Inc Options
This article provides a detailed financial overview of Inspire Medical Systems Inc (INSP), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, analyst recommendations, and insider/institutional ownership details. The data suggests a company with significant sales growth in the past but facing challenges in EPS projections and long-term stock performance.
Edwards Lifesciences stock hits 52-week high at 92.94 USD By Investing.com
Edwards Lifesciences (EW) stock reached a 52-week high of $92.94, trading slightly above this at $92.98, reflecting a 20.09% increase over the past year. Despite its strong market performance, InvestingPro analysis suggests the stock is overvalued. Recent news includes positive clinical trial data for its TAVR procedure, a favorable proposed National Coverage Decision memo for TAVR by the U.S. government, revised price targets from analysts, and a new CFO appointment.
Edwards Lifesciences stock hits 52-week high at 92.94 USD By Investing.com
Edwards Lifesciences (EW) stock reached a new 52-week high of $92.94, trading near its peak at $92.98, reflecting a 20.09% increase over the past year. Despite a high P/E ratio of 50.01 and an "overvalued" assessment by InvestingPro, the company shows strong market performance and investor confidence. Recent developments include positive clinical trial data, a favorable proposed National Coverage Decision memo for TAVR, and a leadership change with a new CFO, alongside encouraging analyst ratings.
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
This article compiles the latest analyst rating changes and price target adjustments for ten different companies, including Replimune Group Inc, Strategy Inc, Watts Water Technologies Inc, Comcast Corp, State Street Corp, Owens Corning, BioCryst Pharmaceuticals Inc, Edwards Lifesciences Corp, Taysha Gene Therapies Inc, and Darden Restaurants Inc. Several analysts upgraded stocks or raised their price targets, indicating a positive outlook for these companies. Notably, Argus Research raised the price target for Darden Restaurants Inc.
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Edwards Lifesciences Corp. (EW) stock increased by 1.69% to $91.99 on Wednesday, defying a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both fell. The company's stock closed just shy of its 52-week high of $92.88. This performance indicates a strong trading day for Edwards Lifesciences compared to its competitors.
Edwards Lifesciences highlights heart valve portfolio as investors watch long-term growth
Edwards Lifesciences is a leading medical technology company focusing on heart valves and critical care monitoring systems. The company's products, especially in transcatheter aortic valve replacement, address the growing demand for minimally invasive procedures in an aging population. Investors are keen on the company's long-term growth potential in structural heart therapies and its recurring revenue from critical care monitoring equipment and services.
NVCR - NovoCure Ltd Volatility & Greeks
This article provides a detailed financial overview of NovoCure Ltd (NVCR), including its stock performance, key financial metrics, and volatility. It highlights the company's market capitalization, income, sales, and various financial ratios, alongside insider ownership and institutional transactions. The data also covers its recent stock changes, volume, and performance over different periods.
Edwards Lifesciences CVP Daniel Lippis sells $56k in stock By Investing.com
Daniel J. Lippis, Corporate Vice President at Edwards Lifesciences, sold 619 shares of company stock for $56,576, which occurred while the stock was trading near its 52-week high and considered overvalued. Simultaneously, he acquired 619 shares through employee stock options for $44,988. These transactions follow positive analyst reactions to new clinical trial data and a proposed National Coverage Decision, alongside the appointment of a new CFO.
Form 4 Edwards Lifesciences Corp For: 30 June By Investing.com
This article from Investing.com is a regulatory filing update, specifically a Form 4 for Edwards Lifesciences Corp for the period ending June 30. It provides no further details beyond the title and the company involved.
Edwards Lifesciences CVP Daniel Lippis sells $56k in stock
Daniel J. Lippis, Corporate Vice President at Edwards Lifesciences, sold 619 shares of company stock for over $56,000 on June 30, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurred while the stock was trading near its 52-week high and is considered overvalued by InvestingPro data. Concurrently, Lippis also exercised options to acquire an equal number of shares at a lower price.
Edwards Lifesciences (NYSE: EW) exec sells 619 shares under 10b5-1 plan
Daniel J. Lippis, Corporate Vice President of Edwards Lifesciences, exercised employee stock options to acquire 619 shares at $72.68 per share and immediately sold them at a weighted average price of $91.4002 per share. These transactions, totaling approximately $56,577, were executed on June 30, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in February 2026. Following these trades, Lippis directly holds 40,410.9103 shares of common stock and 5,571 employee stock options.
Form 4 Edwards Lifesciences Corp For: 30 June By Investing.com
This article reports on a Form 4 filing for Edwards Lifesciences Corp for the period ending June 30. Form 4 filings disclose transactions by company insiders, like officers, directors, or beneficial owners, and are often used by investors to gauge management's sentiment about the company's future. The article itself is brief, primarily serving as a notification about this regulatory filing.
EW - Edwards Lifesciences Corp Latest SEC Filings
This article provides the latest SEC filing information for Edwards Lifesciences Corp (EW), detailing various financial metrics, stock performance data, and insider/institutional ownership figures. It also includes key company statistics such as market cap, P/E ratio, sales, and employee count, alongside a summary of recent earnings and sales performance.
BTIG Adjusts Price Target on Edwards Lifesciences to $110 From $100, Maintains Buy Rating
BTIG has raised its price target for Edwards Lifesciences (NYSE: EW) from $100 to $110, while reiterating a "Buy" rating on the stock. This adjustment comes shortly after Edwards Lifesciences secured US FDA approval for its Ecliptis System and was added to the Russell Midcap Value Benchmark. Other recent news includes the company's strong revenue growth potential due to technological leadership, according to RBC, and several insider share sales.
Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic
Edwards Lifesciences has received FDA clearance for its Ecliptis left atrial appendage (LAA) exclusion system, positioning it to compete with existing devices from AtriCure and Medtronic. This device aims to prevent blood clot formation in LAA, reducing stroke risk in atrial fibrillation patients, especially those who cannot tolerate blood thinners. Edwards plans a measured rollout leveraging its established surgical valve infrastructure.
Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic
Edwards Lifesciences has received FDA clearance for its Ecliptis left atrial appendage exclusion system, positioning it to compete with AtriCure's AtriClip and Medtronic's Penditure system. The device aims to prevent stroke in atrial fibrillation patients by closing the LAA. Edwards plans a targeted rollout, leveraging its existing surgical valve infrastructure.
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Edwards Lifesciences Corp. (EW) rose 1.18% to $90.78 on Friday, outperforming the S&P 500 and Dow Jones Industrial Average, which both saw slight declines. This marks the fourth consecutive day of gains for the stock during a challenging trading session.
Reverse split and 20-vote Class B stock in Picard Medical (PMI) proxy
Picard Medical (PMI) is holding its annual meeting on July 17, 2026, where stockholders will vote on several key proposals including the election of directors, executive compensation, and the ratification of their auditor. Crucially, the company is seeking approval for a reverse stock split (1-for-15 to 1-for-50) to address NYSE American listing non-compliance due to recurring equity deficits. Additionally, a new Class B common stock with 20 votes per share is proposed, which could significantly concentrate voting power and impact existing common stockholders.
Edwards brings fresh valve data to New York, with TAVR study update
Edwards Lifesciences presented new data at New York Valves 2026, reinforcing its leadership in structural heart therapies. The data included baseline characteristics from the PROGRESS trial on moderate aortic stenosis, seven-year durability findings for the SAPIEN 3 platform from the PARTNER 3 trial, and real-world outcomes for its mitral and tricuspid portfolio. The company highlighted its commitment to advancing care, deepening understanding of various heart conditions, and improving patient outcomes globally.
Abbott Laboratories' Q2 2026 Earnings: What to Expect
Abbott Laboratories (ABT) is set to release its Q2 2026 earnings before market open on July 16, with analysts forecasting an adjusted EPS of $1.28. The company's stock has underperformed the S&P 500 over the past year, partly due to a lowered 2026 EPS forecast after acquiring Exact Sciences, and concerns about its nutrition business and competitive pressures. Despite these challenges, analysts maintain a "Strong Buy" rating with a substantial potential upside.
Needham Remains Bullish On Medtronic (MDT) Amid Renal Device Growth
Needham reiterated a "Buy" rating and a $101.00 price target on Medtronic (MDT) due to the strong growth in its renal denervation business, particularly with the Symplicity Spyral System. Sales for this technology are at an annualized rate of $100 million, leading Needham to expect it to contribute significantly to Medtronic's future revenue growth. Despite this, they also noted potential competition in other medical device areas.
Needham Remains Bullish On Medtronic (MDT) Amid Renal Device Growth
Needham has reaffirmed its "Buy" rating and $101.00 price target for Medtronic (MDT) following a review of the company's renal denervation business. The firm noted the Symplicity Spyral system received FDA approval in November 2023 and Medicare coverage began in October 2025, with sales currently at an annualized rate of $100 million. Despite a slight revision in expected revenue contribution from this technology, Needham believes it will help Medtronic maintain revenue growth above 6% in the coming years.
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Edwards Lifesciences Corp. (EW) stock increased by 3.12% to $89.66 on Wednesday. This performance outpaced competitors on a mixed trading day, marking the stock's second consecutive day of gains. The Dow Jones Industrial Average rose, while the S&P 500 Index experienced a slight decline.
Edwards Lifesciences stock hits 52-week high at 89.7 USD By Investing.com
Edwards Lifesciences Corp (EW) stock reached a 52-week high of $89.77, reflecting significant investor confidence and a 16.54% increase over the past year. The company reported strong Q1 2026 financial results, with increased revenue and earnings per share, and positive analyst outlooks, including a reiterated Buy rating from TD Cowen. Regulatory developments regarding transcatheter aortic-valve replacement (TAVR) are also expected to benefit the medical device firm.
Edwards Lifesciences stock hits 52-week high at 89.7 USD
Edwards Lifesciences (EW) stock recently hit a 52-week high of $89.77, reflecting a significant 16.54% increase over the past year and a market capitalization of $51.66 billion. This surge is supported by strong Q1 2026 financial results, positive analyst ratings from TD Cowen and Leerink, and favorable regulatory developments for TAVR. The company also announced Theodora Mistras as its new CFO.
Edwards Lifesciences stock hits 52-week high at 89.7 USD By Investing.com
Edwards Lifesciences stock has reached a new 52-week high of $89.77, reflecting a significant 16.54% increase over the past year and strong investor confidence. This surge follows impressive first-quarter 2026 financial results, with increased revenue and earnings per share, and positive analyst outlooks, including a reiterated Buy rating from TD Cowen. Regulatory developments regarding transcatheter aortic-valve replacement (TAVR) coverage are also expected to further benefit the company.
Edwards Lifesciences stock hits 52-week high at 89.7 USD By Investing.com
Edwards Lifesciences (EW) stock has reached a 52-week high of $89.77 USD, indicating strong investor confidence and positive market sentiment. This milestone follows impressive first-quarter 2026 financial results, with revenue up 12.7% and EPS up 22%, surpassing analyst estimates. Positive regulatory developments for transcatheter aortic-valve replacement (TAVR) are also expected to benefit the medical device company.
Edwards Lifesciences stock hits 52-week high at 89.7 USD
Edwards Lifesciences stock reached a 52-week high of $89.77, reflecting investor confidence and positive market sentiment, with a market capitalization of $51.66 billion and a P/E ratio of 46.71. The company reported strong Q1 2026 financial results, surpassing analyst estimates, and is expected to benefit from favorable regulatory developments regarding TAVR procedures. Several analysts have reiterated positive ratings and raised price targets for the medical technology firm.
Edwards Lifesciences stock hits 52-week high at 89.7 USD By Investing.com
Edwards Lifesciences stock reached a 52-week high of $89.77 USD, reflecting strong investor confidence and a 16.54% increase over the past year. The medical device company reported impressive Q1 2026 financial results with increased revenue and earnings per share, surpassing analyst estimates. Positive regulatory developments for transcatheter aortic-valve replacement (TAVR) and analyst reiterations of Buy ratings further underscore the company's strong market position and future prospects.
Edwards Lifesciences stock hits 52-week high at 89.7 USD By Investing.com
Edwards Lifesciences stock has reached a 52-week high of $89.77, reflecting strong investor confidence and a 16.54% increase over the past year. The medical device company reported impressive Q1 2026 financial results, with revenue up 12.7% and EPS up 22%, surpassing analyst expectations. Regulatory developments regarding transcatheter aortic-valve replacement (TAVR) coverage are also seen benefiting the company, leading to positive analyst ratings and raised price targets.
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors despite daily gains
Edwards Lifesciences Corp. (EW) shares rose 1.25% on Tuesday, closing at $86.95, even as the broader market saw declines with the S&P 500 falling 1.44% and the Dow Jones Industrial Average dropping 0.09%. Despite its daily gain, the stock underperformed when compared to some competitors and closed 2.96% below its 52-week high of $89.60.
Edwards Lifesciences clears fresh Medicare hurdle, shares consolidate after 52-week high
Edwards Lifesciences has received a positive Medicare coverage proposal for its heart valve technology, supporting the expansion of access to transcatheter aortic valve replacement procedures. This news has bolstered investor confidence, with the company's shares trading just below a recent 52-week high. Analysts highlight the clearer reimbursement framework and the potential for increased procedural volumes as key growth drivers for the structural heart therapy specialist.
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors
Edwards Lifesciences Corp. (EW) stock fell 1.69% on Monday, closing at $85.88, despite a mixed trading session for the broader market. This performance left the company's stock 4.15% below its 52-week high of $89.60, reached on June 16th. The Dow Jones Industrial Average rose, while the S&P 500 Index declined.
Bruker Corp (BRKR) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Bruker Corp (BRKR), including its current earnings forecast score, average analyst price target, and a breakdown of analyst ratings. It also addresses frequently asked questions about expected revenue, price targets, and past EPS performance. The data indicates a "Buy" trend based on analyst consensus, with an anticipated next-quarter EPS of $0.39 and revenue of $853.39M.
AxoGen Inc (AXGN) Earnings Forecast: Future EPS & Revenue Growth Estimates
AxoGen Inc (AXGN) currently holds an earnings forecast score of 8.40, ranking 37th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $36.00 for AXGN, with forecasts ranging from $27.00 to $40.00. The consensus among 10 analysts is a "Buy" rating for the stock.
Varex Imaging Corp (VREX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Varex Imaging Corp (VREX) currently has an earnings forecast score of 8.40 and a consensus price target of $18.00 from five analysts, indicating a 71.43% upside. The company's stock is rated a "Buy" by most analysts, with an expected revenue of $214.94 million for the next quarter and an anticipated EPS of $0.27.
IRadimed Corp (IRMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for IRadimed Corp (IRMD), indicating an earnings forecast score of 8.00 and ranking 66th in its industry. Analysts, based on 2 ratings, have an average price target of $99.00 with a "Buy" recommendation. The company's previous quarter EPS was $0.51 against an expectation of $0.46, with the next quarter's EPS expected at $0.42 and revenue at $20.35M.
